Silver Book

Silver Book Fact

Treatment of patients with advanced dry age-related macular degeneration (AMD) with ciliary neurotrophic factor (CNTF) implants resulted in stabilization of visual acuity.  A sub-group analysis found that 100% of patients receiving a high-dose lost <15 letters of acuity–compared with 55.6% in the combined low-dose/sham group.  The high-dose group had a 0.6 mean letter gain while the low-dose/sham group had a mean 9.7 letter loss.

Zhang, Kang, Jill J. Hopkins, Jeffrey S. Heier, David G. Birch, Lawrence S. Halperin, Thomas A. Albini, David M. Brown, Glenn J. Jaffe, Weng Tao, and George A. Williams. Ciliary Neurotrophic Factor Delievered by Encapsulated Cell Intraocular Implants for Treatment of Geographic Atrophy in Age-Related Macular Degeneration. PNAS. 2011; 108(15). http://www.pnas.org/content/early/2011/03/24/1018987108

Reference

Title
Ciliary Neurotrophic Factor Delievered by Encapsulated Cell Intraocular Implants for Treatment of Geographic Atrophy in Age-Related Macular Degeneration
Publication
PNAS
Publication Date
2011
Authors
Zhang, Kang, Jill J. Hopkins, Jeffrey S. Heier, David G. Birch, Lawrence S. Halperin, Thomas A. Albini, David M. Brown, Glenn J. Jaffe, Weng Tao, and George A. Williams
Volume & Issue
Volume 108, Issue 15
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Of the 8 million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years. However, the NEI-sponsored Age-Related Eye…  
  • Intensive Glycemic Control in People with Diabetes
    Intensive glycemic control in diabetics reduced their: Adjusted mean risk of DR by 76% Risk of progression by 54% Rates of laser surgery by 56% Risk of DME by 23%    
  • It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%,…  
  • DR Treatment Reduced Risk of Blindness
    Appropriate treatment can reduce the risk of blindness or moderate vision loss from DR by more than 90%.  
  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.